[1] Murray, A.M., Bennett, D.A., Mendes de Leon, C.F., Beckett, L.A. and Evans, D.A. (2004) A longitudinal study of Parkinsonism and disability in a community population of older people. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 59, 864-870. doi:10.1093/gerona/59.8.M864
[2] Lauretani, F., Maggio, M., Silvestrini, C., Nardelli, A., Saccavini, M. and Ceda, G.P. (2012) Parkinson’s disease (PD) in the elderly: an example of geriatric syndrome (GS)? Archives of Gerontology and Geriatrics, 54, 242-246. doi:10.1016/j.archger.2011.03.002
[3] Jankovic, J. (2008) Parkinson’s disease: Clinical features and diagnosis. Journal of Neurology, Neurosurgery & Psychiatry, 79, 368-376. doi:10.1136/jnnp.2007.131045
[4] Lees, A. (2010) The bare essentials: Parkinson’s disease. Practical Neurology, 10, 240-246. doi:10.1136/jnnp.2010.217836
[5] Lauretani, F., Maggio, M., Nardelli, A. and Ceda, G.P. (2012) Parkinson’s disease: Diagnosis, treatment and prognosis. In: Yoshida, C. and Ito, A., Eds., Treatment of Parkinson’s Disease and Parkinsonism in the Elderly, Nova Science Publishers, New York, pp. 165-178.
[6] Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A., Jansen Steur, E.N. and Braak, E. (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging, 24, 197-211. doi:10.1016/S0197-4580(02)00065-9
[7] Ahlskog, J.E. and Muenter, M.D. (2001) Frequency of levodopa related dyskinesias and motor fluctuations as estimated from the cumulative literature. Movement Disorders, 16, 448-458. doi:10.1002/mds.1090
[8] Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., et al. (2006) Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European federation of neurological societies and the movement disorder society—European Section. Part I: Early (uncomplicated) Parkinson’s disease. European Journal of Neurology, 13, 1170-1185. doi:10.1111/j.1468-1331.2006.01547.x
[9] Olanow, C.W., Stern, M.B. and Sethi, K. (2009) The scientific and clinical basis for the treatment of Parkinson disease. Neurology, 72, S1-136. doi:10.1212/WNL.0b013e3181a1d44c
[10] Fasano, A., Guidubaldi, A., De Nigris, F. and Bentivoglio, A.R. (2011) Safety and efficacy of rotigotine in individuals with Parkinson’s disease aged 75 and older. Journal of the American Geriatrics Society, 59, 2386-2387. doi:10.1111/j.1532-5415.2011.03689.x
[11] Goetz, C.G., Tilley, B.C., Shaftman, S.R., Stebbins, G.T., Fahn, S., Martinez-Martin, P., et al. (2008) Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 23, 2129-2170. doi:10.1002/mds.22340
[12] Inouye, S.K., van Dyck, C.H., Alessi, C.A., Balkin, S., Siegal, A.P. and Horwitz, R.I. (1990) Clarifying confusion: The confusion assessment method. A new method for detection of delirium. Annals of Internal Medicine, 113, 941-948. doi:10.7326/0003-4819-113-12-941
[13] Ravina, B., Marder, K., Fernandez, H.H., Friedman, J.H., McDonald, W., Murphy, D., Aarsland, D., et al. (2007) Diagnostic criteria for psychosis in Parkinson’s disease: Report of an NINDS/NIMH work group. Movement Disorders, 22, 1061-1068. doi:10.1002/mds.21382
[14] Lauretani, F., Caffarra, P., Ruffini, P., Nardelli, A., Ceda, G.P., Maggio, M., et al. (2011) Brief practical clinical diagnostic criteria for the neurodegenerative diseases in the elderly. Drugs and Therapy Studies, 1, e6.
[15] Lauretani F., Ceda, G.P., Maggio, M., Nardelli, A., Saccavini, M. and Ferrucci, L. (2010) Capturing side-effect of medication to identify persons at risk of delirium. Aging Clinical and Experimental Research, 22, 456-458.
[16] LeWitt, P.A., Lyons, K.E. and Pahwa, R. (SP 650 Study Group) (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology, 68, 1262-1267. doi:10.1212/01.wnl.0000259516.61938.bb
[17] Watts, R.L., Jankovic, J., Waters, C., Rajput, A., Boroojerdi, B. and Rao, J. (2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology, 68, 272-276. doi:10.1212/01.wnl.0000252355.79284.22
[18] Hely, M.A., Reid, W.G., Adena, M.A., Halliday, G.M. and Morris, J.G. (2008) The Sydney multicenter study of Parkinson’s disease: The inevitability of dementia at 20 years. Movement Disorders, 23, 837-844.